Strattera 40 mg

Generic Name: Atomoxetine

Strattera  (Atomoxetine) is used to treat attention-deficit hyperactivity disorder (ADHD). It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters). It may help to increase the ability to pay attention, concentrate, stay focused, and stop fidgeting.
Strattera contains atomoxetine Hcl, which is a selective norepinephrine reuptake inhibitor of presynaptic norepinephrine vectors used to treat attention deficit hyperactivity disorder (ADHD). Manifestations of ADHD detected in more than one social environment include lack of concentration, distractibility, excessive restlessness, impulsiveness, disorganization, restlessness, and other similar conduct disorders.

Dosage and directions
Take it once or twice daily with or without food. Take the capsules whole, do not crush them and sprinkle on food. If Strattera should be canceled, it does not require a gradual reduction of the dose. The recommended initial dose in children, adolescents and adults with body weight over 70 kg is 40 mg. It should be increased to a therapeutic daily dose of 80 mg not earlier than in three days. If the symptoms do not improve the maximal daily dose of Strattera may be increased to maximal daily dose of 120 mg not earlier than 2-4 weeks after start of the treatment. Take exactly as prescribed by your doctor, do not take more of this medication than your doctor recommended.

Precautions
Inform your doctor if you have hypertension, tachycardia, cardiovascular or cerebrovascular circulation disorders, congenital heart defect, coronary artery disease, heart disease, a heart rhythm disorder, high or low blood pressure, heart attack not so long ago, or have a condition which can cause arterial hypotension. Notify your doctor if you have liver disease, high or low blood pressure, problems with urination, and also bipolar illness, mental illness, psychotic disorder, depression, or suicide attempt in history. It is not known how this medication may affect an unborn baby so Strattera should be administered to pregnant women only if a potential benefit from it use exceeds possible risks.